EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Multi-Enzyme Peptide Mapping of Site-Selective Trastuzumab Modification by an Engineered Thermostable Microbial Transglutaminase

Natsuki Shikida, Shunsuke Yamazaki iD, Tomohiro Watanabe iD, Haru Marumo, Kazutoshi Takahashi iD, Yutaka Matsuda iD, Kazutaka Shimbo

ACS Omega · 03.11.2026 · 11 (43) · 66259-66267

DOI: 10.1021/acsomega.6c04702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 19.10.2026. Verfasst von Natsuki Shikida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kanagawa 210-8681, Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ajinomoto.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptide mapping by liquid chromatography-tandem mass spectrometry (LC–MS/MS) is a key analytical strategy for residue-level characterization of antibody conjugates, providing modification-site assignments and apparent relative modification estimates that complement intact-mass and chromatographic drug-to-antibody ratio (DAR) measurements. The development of homogeneous antibody-drug conjugates (ADCs) relies on precise control of the conjugation site and DAR. For site-selectively modified ADCs, in which amino acid-level homogeneity is an important quality attribute, peptide mapping is therefore not only a confirmatory assay but also a central component of structural characterization. However, its reliability depends on enzymatic coverage and sample-handling conditions that affect the recovery of hydrophobic Fc-derived peptides, particularly in conjugates generated at high modification levels. In this study, we evaluated a multi-enzyme LC–MS/MS peptide-mapping workflow for antibody conjugates generated by microbial transglutaminase (MTG)-mediated Fc modification, using trastuzumab conjugated with dansylcadaverine (DNC) as a model system. An engineered thermostable MTG variant carrying five amino acid substitutions (D3C/S101P/G157S/G250R/G283C) was used to prepare a highly modified trastuzumab-DNC conjugate for evaluation of complementary protease coverage, residue-level modification-site assignment, and recovery of hydrophobic Fc-derived peptides. The engineered MTG was also compared with the commercial MTG formulation Activa using glycosylated trastuzumab under the specified nominal enzyme-loading conditions. Because this comparison was not normalized on the basis of catalytic activity under the antibody-conjugation conditions, it was treated as a formulation-based reference and was not used to establish intrinsic superiority of either enzyme preparation. Complementary digestion with trypsin, chymotrypsin, and Glu-C provided convergent evidence that DNC modification was predominantly localized to heavy-chain Q298 and enabled evaluation of other detectable glutamine-containing peptides. We further found that post-digestion addition of guanidine hydrochloride (GnHCl) during quenching increased the recovery of hydrophobic Fc-derived peptides, most notably the Q298-containing peptides. Omission of GnHCl during quenching reduced the recovery of several hydrophobic Fc-derived peptides and could bias peptide-map-based apparent modification estimates under the tested conditions. Under the optimized workflow, Q298 consistently showed the highest peptide-map-based apparent modification level, whereas apparent modification levels at other unambiguously assigned glutamine residues remained low under the tested conditions. However, these peak-area-based values do not represent absolute molar occupancy, and low-abundance off-site modifications below the analytical detection threshold cannot be excluded. These findings demonstrate that multi-enzyme peptide mapping combined with denaturant-assisted quenching provides a practical analytical workflow for residue-level characterization of highly modified, site-selective antibody conjugates. The workflow supports predominant modification at heavy-chain Q298 under the tested conditions and highlights the importance of sample-preparation optimization in peptide mapping-based characterization of ADCs and related antibody conjugates. Because DNC is a model primary amine, application of this workflow to therapeutic ADC linker-payloads will require substrate-specific optimization and analytical qualification.

Autor:innen und Institutionen

  • Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kanagawa 210-8681, Japan.

ORCID-Profile: Shunsuke Yamazaki, Tomohiro Watanabe, Kazutoshi Takahashi, Yutaka Matsuda

Förderung

  • Ajinomoto

Zitieren

APA

Shikida, N., Yamazaki, S., Watanabe, T., Marumo, H., Takahashi, K., Matsuda, Y., & Shimbo, K. (2026). Multi-Enzyme Peptide Mapping of Site-Selective Trastuzumab Modification by an Engineered Thermostable Microbial Transglutaminase. ACS Omega, 11(43), 66259-66267. https://doi.org/10.1021/acsomega.6c04702

Vancouver

Shikida N, Yamazaki S, Watanabe T, Marumo H, Takahashi K, Matsuda Y, et al. Multi-Enzyme Peptide Mapping of Site-Selective Trastuzumab Modification by an Engineered Thermostable Microbial Transglutaminase. ACS Omega. 2026;11(43):66259-66267. doi:10.1021/acsomega.6c04702

BibTeX
@article{Shikida2026,
  author = {Shikida, Natsuki and Yamazaki, Shunsuke and Watanabe, Tomohiro and Marumo, Haru and Takahashi, Kazutoshi and Matsuda, Yutaka and Shimbo, Kazutaka},
  title = {Multi-Enzyme Peptide Mapping of Site-Selective Trastuzumab Modification by an Engineered Thermostable Microbial Transglutaminase},
  journal = {ACS Omega},
  year = {2026},
  volume = {11},
  number = {43},
  pages = {66259--66267},
  doi = {10.1021/acsomega.6c04702}
}
Kostenlos starten →